Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca wins European approval for Tagrisso

The first-in-class lung cancer treatment receives a conditional licence

AstraZeneca Tagrisso pills

AstraZeneca has secured EU approval for Tagrisso, its first-in-class treatment for non-small cell lung cancer (NSCLC).

The drug was cleared through the European Medicines Agency's (EMA) accelerated assessment procedure for conditional marketing authorisation, and so will be up for further review in one year.

Tagrisso (osimertinib) is a third-generation EGFR inhibitor and the first indicated to treat adults with metastatic EGFR T790M mutation-positive NSCLC.

It's designed to target both the EGFR mutation that triggers cancer development and the T790M mutation that creates resistance against existing NSCLC treatments.

Almost two thirds of patients treated with older treatments such as AstraZeneca's Iressa (gefitinib), Boehringer Ingelheim's Giotrif (afatinib) or Roche/Astellas' Tarceva (erlotinib) develop the T790M mutation and face limited treatments options.

Sean Bohen, AstraZeneca's executive vice president, global medicines development and chief medical officer said Tagrisso “defines a new generation of targeted EGFR-TKI treatments”.

“The European Commission's expedited approval reflects the importance of this innovative medicine for addressing the needs of patients with lung cancer who have the T790M mutation,” he added.

Patients' eligibility for treatment with Tagrisso is determined through a blood test or tumour sample, for which a number of diagnostics are available.

Chairman of the Global Lunch Cancer Coalition Dr Matthew Peters said: “It is an exciting time in the care of patients with lung cancer.

“The ability to precisely characterise patients who have different types of lung cancer based on genetic mutations, and predict their response to targeted treatments, offers a more accurate and efficient approach to lung cancer care.”

In 2012 more than 1.25 million people died from cancer in the EU and lung cancer is the leading cause of cancer death among both men and women, accounting for about one-third of all cancer deaths.

NSCLC accounts for 80-85% of cases and the EGFR mutation form occurs in 10-15% of NSCLC patients in Europe.

The European Commission's approval of Tagrisso comes shortly after the drug's recommendation by EMA scientific advisors in December and follows its November approval in the US, where it also become the first drug approved for patients with T790M-positive NSCLC who have progressed on or after EGFR inhibitor therapy.

Article by
Rebecca Clifford

4th February 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Shining our spotlight on… the patient
The second issue of our new SPOTLIGHT ON series is live! In this issue, we discuss the role of patient insights and what impact it has on improving patient outcomes...
Healthcare in the Digital Age
Healthcare is changing. By understanding the needs of the physicians, and using innovative channels to make meaningful connections, pharma can ensure it continues to enjoy a mutually beneficial relationship....
Opinion piece: Patient-centricity and pharma – where are we now?
Patient-centricity is a term that has gained currency in the pharma industry in recent years, and most major companies in the sector are now dedicating resources to ensure that they...

Infographics